Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing its Impact on T Regulatory Cell and NK Cell Populations

Overview of attention for article published in Journal of Investigative Dermatology, September 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 1 news outlet

twitter: 9 X users

Readers on

mendeley: 42 Mendeley

So far, Altmetric has seen 9 X posts from 9 X users, with an upper bound of 16,134 followers.

https://t.co/QhWEL0dR2O The trial failure was further recapitulated in the C3H/HeJ AA mouse model. Using an IL-2-IL-2 antibody fusion protein failed rescuing established AA.

2021: Low-Dose IL-2 for Treating Alopecia Areata, 52-Wk Placebo-Controlled Study 🔹 #Treg increased 🔹 50% reduction in SALT: 14% LD IL-2 v 9% Placebo Conclusions: No significant improvement Failed to significantly stimulate hair regrowth https://t.co…

@A_May_MD https://t.co/DsGmbbbMMS -> this is the negative ph 2 study

RT @CHUdeNice: 👏Bravo au Dr Le Duff, #dermatologue au #CHUdeNice, pour l'étude sur les effets de faibles doses d’IL-2 dans les #peladessévè…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 5 additional X posts.